BASF introduces Kollicoat MAE 100-55 for formulation of enteric film coatings

Published: 4-Apr-2016
Ingredients

Easier handling due to dust-free material


BASF has added Kollicoat MAE 100-55 to its portfolio of functional excipients for instant and modified release.

The German firm says the product can directly replace comparable pH >5.5 enteric release materials in commercial formulations. As it matches the release profile and complies with applicable regulatory monographs, it can be used today without re-registration.

BASF says the superior size of the dried powder particles delivers dust-free handling, thus making operations easy, efficient and clean.

Kollicoat MAE 100-55 also provides equivalent drug release as existing comparable products in the market, the firm says.

'Kollicoat MAE 100-55 extends our offer of pH >5.5 enteric release coatings based on methacrylic acid-ethylacrylate copolymer, providing pharmaceutical manufacturers [with] more flexibility and supply security,' says Kai Sievert, Head of Global Marketing Pharma Solutions at BASF.

  • Companies:
  • BASF Personal Care and Nutrition GmbH
See more

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Read more
Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Rousselot Biomedical launches EU MDR compliant gelatin range From May 2024, all devices placed on the European market must conform with the EU Medical Device Regulation (MDR)
  3. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  4. Rousselot Biomedical introduces GMP-grade GelMA GMP status allows for the ingredient’s use in clinical and in-body applications
  5. Lonza At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of around 17,500 skilled employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. <br> <br> By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases.

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community
Ingredients

BASF completes acquisition of Chemetall

BASF has completed its acquisition of Albemarle’s global surface treatment business, Chemetall
Ingredients

BASF inaugurates new PVP production facility in Shanghai, China

Will produce PVP K30 powder used as a base for pharma excipients and cosmetics
Ingredients

Colorcon to purchase BASF’s Kollicoat IR coating system product line

The two firms will also further their cooperation to offer superior functional coatings for pharmaceutical tablets
Manufacturing

BASF establishes speciality amine production plant in Ludwigshafen

BASF’s Intermediates division develops, produces and markets more than 700 intermediates, including amines, diols, polyalcohols and acids
Ingredients

BASF to develop high purity poloxamer for Mast Therapeutics

To be used for treating specific therapeutic indications
Manufacturing

BASF introduces Kollicoat IR

Wet binder for peroxide-sensitive active pharmaceutical ingredient formulations
Subscribe now